Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease

Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn’s disease (CD) and ulcerative colitis (UC) in several phase III trials. Mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Lichnog, Charlotte, Klabunde, Sha, Becker, Emily, Fuh, Franklin, Tripal, Philipp, Atreya, Raja, Klenske, Entcho, Erickson, Rich, Chiu, Henry, Reed, Chae, Chung, Shan, Neufert, Clemens, Atreya, Imke, McBride, Jacqueline, Neurath, Markus F., Zundler, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367223/
https://www.ncbi.nlm.nih.gov/pubmed/30774593
http://dx.doi.org/10.3389/fphar.2019.00039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367223/
https://www.ncbi.nlm.nih.gov/pubmed/30774593
http://dx.doi.org/10.3389/fphar.2019.00039

Ejemplares similares